MNI: GERMANY GFK DECEMBER CONSUMER CLIMATE -23.3

MNI BRIEF: BOJ’s JGB Unrealised Loss Rises To JPY13.7 Tlrn

MNI BRIEF: Riksbank Dec Cut On If Things Hold - Jansson

RPT:- MNI NOV CHINA MONEY MARKET INDEX 53.5 VS OCT 38.4

MNI NOV CHINA MONEY MARKET INDEX 53.5 VS OCT 38.4

MNI BRIEF: China Profits Fall In October Y/Y

MNI: FRANCE NOV CONSUMER SENTIMENT 90

RBNZ SEES RISK OF MID-TERM INFLATION VOLATILITY

MNI: RBNZ CUTS OCR 50BP TO 4.25%

AUSTRALIA: 2025 Election Outcome Looking More Uncertain According To Newspoll

MNI EXCLUSIVE: German Turmoil Dashes EU's Joint-Funding Hopes -Officials

© 1982-2024 MNI. All rights reserved.
Terms | Privacy
Log Out
Free Trial

HEALTHCARE: Sanofi (SANFP: A1 pos / AA): Consumer Unit Sale Imminent

HEALTHCARE
BulletCredit Bullets
  • Bloomberg are reporting that banks and private credit have lined up €10bn in financing for a takeover of the Consumer Health unit
  • The total price tag was said to be $20bn back in June
  • Sanofi may keep a significant minority stake to use as liquidity in the future
  • Sanofi needs to use the proceeds to replace its pipeline given that Dupixent is 28% of sales
  • No immediate credit impact for Sanofi
  • Consumer Unit is 11% of sales
72 words

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.
  • Bloomberg are reporting that banks and private credit have lined up €10bn in financing for a takeover of the Consumer Health unit
  • The total price tag was said to be $20bn back in June
  • Sanofi may keep a significant minority stake to use as liquidity in the future
  • Sanofi needs to use the proceeds to replace its pipeline given that Dupixent is 28% of sales
  • No immediate credit impact for Sanofi
  • Consumer Unit is 11% of sales